This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

David J. Weber, MD; William A. Rutala, PhD; Stephanie A. Kenyear, RN; Stanley M. Lemon, MD
University of North Carolina School of Medicine Chapel Hill

JAMA. 1986;255(16):2157.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

We recently reported a multivariate analysis of the risk factors associated with a poor immunogenic response to the hepatitis B plasma vaccine among 194 employees of a community hospital.¹ The vaccine had been stored and administered according to manufacturer's recommendations. Employees received all three doses of the vaccine in the buttock with a 2.5-cm, 23-gauge needle. Overall, only 56% (108/194) of the employees developed antibody to hepatitis B surface antigen (anti-HBs) as measured by the enzyme-linked immunosorbent assay (Abbott). A high body weight-height index (a measure of obesity) was found to be predictive of a lack of antibody response.

To date, 41 of the 86 employees who initially failed to develop anti-HBs have received two additional doses of the vaccine in the deltoid using a 2.5-cm, 23-gauge needle. The initial repeated immunization was conducted 425 ± 15 days after the completion of the primary series, and . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?